Will be interesting to see how quickly BioHorizons achieves first Singapore Striate+ sales (which I assume would be announced to market) given that they are already deeply ingrained in that market (noting that we’ve cut off the process of having to look for a distributor).
Interesting to note that this Striate+ Singapore approval took 7.5 months to achieve. Remplir Singapore approval also took about 7.5 months. So that’s nice consistency by the Singapore HSA. And is nice to know for more predictability for future approvals. I assume SmrtGraft tendon product might be submitted in Singapore next year, following TGA approval in the near future.
In the days the 9 business days that remain, we could also see announcements DACH region market launch and appointment of US sales team as per last month’s presentation.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)